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X-linked lymphoproliferative syndromes
(XLP) are primary immunodeficiencies
characterized by a particular vulnerability
toward Epstein-Barr virus infection,
frequently resulting in hemophagocytic
lymphohistiocytosis (HLH). XLP type 1
(XLP-1) is caused by mutations in the
gene SH2D1A (also named SAP), whereas
mutations in the gene XIAP underlie XLP
type 2 (XLP-2). Here, a comparison of the
clinical phenotypes associated with XLP-1
and XLP-2 was performed in cohorts of 33
and 30 patients, respectively. HLH (XLP-1,
55%; XLP-2, 76%) and hypogammaglobu-
linemia (XLP-1, 67%; XLP-2, 33%) oc-
curred in both groups. Epstein-Barr virus
infection in XLP-1 and XLP-2 was the
common trigger of HLH (XLP-1, 92%;
XLP-2, 83%). Survival rates and mean
ages at the first HLH episode did not
differ for both groups, but HLH was more
severe with lethal outcome in XLP-1
(XLP-1, 61%; XLP-2, 23%). Although only
XLP-1 patients developed lymphomas
(30%), XLP-2 patients (17%) had chronic
hemorrhagic colitis as documented by
histopathology. Recurrent splenomegaly
often associated with cytopenia and fever
was preferentially observed in XLP-2
(XLP-1, 7%; XLP-2, 87%) and probably
represents minimal forms of HLH as docu-
mented by histopathology. This first phe-
notypic comparison of XLP subtypes
should help to improve the diagnosis and
the care of patients with XLP conditions.
(Blood. 2011;117(5):1522-1529)
Introduction
X-linked lymphoproliferative syndrome (XLP) is a rare immunode-
ficiency condition characterized by an extreme vulnerability to
Epstein-Barr virus (EBV) infection, frequently resulting in hemoph-
agocytic lymphohistiocytosis (HLH) or virus-associated hemoph-
agocytic syndrome (VAHS).1-3 HLH is caused by overwhelming
T-cell and macrophage activation, leading to fever, splenomegaly,
cytopenia, hypofibrinogenemia, or hypertriglyceridemia, hyperfer-
ritinemia, and hemophagocytosis.4
XLP belongs to the group of familial hemophagocytic lympho-
histiocytosis (FHL) as originally proposed by Purtilo et al.1 In the
original description, the term “lymphoproliferative disease” in the
Duncan kindred1 was used for benign or malignant lymphoprolif-
eration but also for the diffuse organ “infiltrates composed of
lymphocytes, plasma cells, and histiocytes, some containing eryth-
rocytes,” describing histologic features of HLH. Thus, the term
“X-linked lymphoproliferative disease or syndrome” used thereaf-
ter to name this condition refers not only to malignant lymphomas
but also to HLH. Two genetic causes are responsible for XLP. XLP
type 1 (XLP-1) is caused by hemizygous mutations in the gene
SH2D1A encoding the signaling lymphocyte activation molecule
(SLAM)–associated protein (SAP) (MIM no. 308240).5,6 Hemizy-
gous mutations in the gene encoding the X-linked inhibitor of
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apoptosis protein (XIAP; also termed BIRC4; MIM no. 300635)
have been discovered in a cohort of patients with clinical XLP
without any identified mutations in SH2D1A and normal SAP
protein expression.7 Thus, mutations in XIAP define the XLP
type 2 (XLP-2). These findings were confirmed by the identifica-
tion of additional patients with XIAP deficiency.8,9 After EBV
infection in most (but not all) cases, patients bearing mutations
in SH2D1A (hereafter denoted SAP-deficient patients) may
experience variable manifestations such as fulminant infectious
mononucleosis corresponding pathophysiologically to HLH,
malignant lymphoma, and hypogammaglobulinemia.2,10,11 Less
common findings are dysgammaglobulinemia, bone marrow
hypoplasia, especially aplastic anemia, and lymphocytic vascu-
litis.12,13 However, although HLH is almost always triggered by
EBV, the other manifestations can be present even in SAP-
deficient patients who have never encountered EBV.2,3,10,11 The
clinical features of the 12 patients with mutations in XIAP
(hereafter denoted XIAP-deficient patients) initially described,
slightly differed from the features described above. In some
XIAP-deficient patients, splenomegaly was noticed as the first
clinical symptom, and chronic colitis occurred during the
disease course in 2 patients.7
The gene product affected in XLP-1 patients, SAP, is a small
SH2-containing adaptor protein that is expressed in T, natural killer
(NK), and invariant NKT (iNKT) cells.5,14 SAP binds with high
affinity and specificity to tyrosine-based motifs located in the
cytoplasmic domains of the transmembrane receptors of the SLAM
family. SAP couples SLAM family receptors to downstream
signaling pathways and thereby enables SLAM receptors to
mediate an array of activating or regulatory signals. In SAP-
deficient humans and mice, multiple cellular defects have been
documented, including altered CD8 T- and NK-cell cytotoxicity
responses, CD4 T helper cell cytokine production and function,
block of CD1d-restricted iNKT-cell development, defective anti-
body production associated with reduced numbers of switched
memory B cells and defects in germinal center formation.11,14
Studies of SAP-deficient humans and mice support the notion that
the immune dysfunctions seen in SAP-deficiency are mostly
caused by alterations in the signal transduction of SLAM family
receptors.
The XLP-2 gene product, XIAP, belongs to the family of
inhibitor of apoptosis proteins and is well known to be a potent
physiologic inhibitor of caspases 3, 7, and 9.15 XIAP is ubiqui-
tously expressed.7 In addition to its antiapoptotic role, XIAP is also
involved in multiple signaling pathways, including copper metabo-
lism, activation of the nuclear factor B and the mitogen-activated
protein kinases pathways and the transforming growth factor-–
receptor and bone morphogenetic protein–receptor signal transduc-
tion.16 In XIAP-deficient patients, lymphocytes are characterized
by an increased susceptibility to apoptosis in response to CD95 and
tumor necrosis factor receptor–related apoptosis-inducing ligand
receptor stimulation as well as enhanced activation-induced cell
death.7 XIAP-deficient patients also display low but detectable
numbers of iNKT cells in blood although a recent study indicated
that they can have normal numbers of iNKT cells.9 NK cell–
mediated cytotoxicity is apparently normal in XIAP-deficient
patients.7,9
Our knowledge of the immune dysfunctions underlying the
clinical manifestations in SAP-deficient patients has been largely
improved in the past decade. However, this is not the case for
XIAP-deficient patients. A better characterization of the clinical
similarities and the differences between XLP-1 and XLP-2 could
provide hints for a better understanding of the pathogenesis of these
conditions and, furthermore, improve diagnostic and therapeutic
procedures for these patients. Therefore, we performed a retrospec-
tive analysis of the clinical features observed in cohorts of 33 SAP-
and 30 XIAP-deficient patients.
Methods
Patients and diagnosis
We performed a retrospective analysis of the clinical and laboratory
features of SAP- and XIAP-deficient patients in whom confirmative
molecular diagnosis had been performed at the Necker Children’s Hospital.
Patient conditions were diagnosed as XLP-1 and XLP-2 on the basis of
molecular results or on the basis of clinical features when disease had been
molecularly proven in male relatives on the mother’s side (supplemental
Methods and Results, available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article). Patients and families
provided informed consent for genetic and immunologic studies in accor-
dance to the 1975 Declaration of Helsinki, and the study was approved by
the local ethics regulations (Necker-Enfants Malades Ethical Board
Committee).
Protein expression
Expression of SAP and XIAP was analyzed by Western blotting or flow
cytometry or both after intracellular staining in phytohemagglutinin-
induced T-cell blasts or peripheral blood mononuclear cells or both as
described.7 The monoclonal antibody (mAb) anti-SAP was kindly provided
by Dr A. Veillette, IRCM, Montre´al. Intracellular SAP was stained by
fluorescein isothiocyanate– or phycoerythrin-coupled anti-SAP mAb
and XIAP detected with noncoupled anti-XIAP mouse mAb (clone 48;
BD Biosciences) revealed with fluorescein isothiocyanate–coupled anti–
mouse antibodies (Jackson ImmunoResearch Laboratories Inc) after cell
permeabilization with Perm 2 (BD Biosciences).
Histology and immunohistochemistry
All diagnostic specimens were fixed in 10% buffered formalin and stained
with hematoxylin and eosin, Giemsa, or trichrome dyes (for the liver).
Immunohistochemistry was performed on fixed tissues with a peroxidase-
based method (Dako). Antibodies used were raised against CD20, CD3,
CD8, and latent membrane protein 1 (LMP-1) (Dako); CD25 (Novocastra);
and T-cell intracellular antigen-1 (Immunotech). EVB-encoded RNA
(EBER) was probed on some specimen with the use of in situ hybridization
technique. Slides were observed using a Leica DM LB microscope with
20,40, and100 objectives and a 10 eyepiece. Acquisition of images
was with IM50 software (Leica Microsystems). All slides were analyzed
by the same pathologist (D.C.), and an independent review was also
performed (F.H.).
Clinical assessment
The patients’clinical events and laboratory features were assessed retrospec-
tively by retrieval of data from medical records.
Statistical analysis
The statistical analyses were performed with Fisher exact tests or log-rank
tests (for comparison of survival curves) with the use of the PRISM
software (GraphPad Software Inc).
Results
XLP-1 was diagnosed in 33 patients from 19 families, and
mutations of SH2D1A were found in 18 families, and XLP-2 was
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diagnosed in 30 patients from 11 families (Tables 1 and 2). In one patient
(PS18.1), no mutation in SH2D1A was found; however, no SAP protein
expression was detected.17 Six and 7 mutations in SH2D1A and XIAP
were novel and not reported, respectively (supplemental Methods and
Results).
Clinical manifestations included HLH, splenomegaly and incom-
plete forms of HLH, lymphoma, dysgammaglobulinemia, colitis,
and rare clinical manifestations.
HLH
The mean age at first episode of HLH was 7.35 years (range,
2.0-19.0 years) in SAP-deficient and 6.5 years (range, 0.1-
23.0 years) in XIAP-deficient patients (P  .89). The occur-
rence of HLH in SAP-deficient (18 of 33, 55%) and in
XIAP-deficient (22 of 29, 76%, one unknown) patients did not
differ significantly (P  .112) (Figure 1A; Table 3). XIAP-
deficient patients with null mutations (families X1 to X7 and
X11) more frequently developed HLH (19 of 20, 95%) com-
pared with XIAP-deficient patients expressing non-null muta-
tions (families X8, X9, and X10; 3 of 9, 33%; **P  .0011;
supplemental Figure 1A).
Overall, 11 of the 33 SAP-deficient patients (33%) and 5 of 30
the XIAP-deficient patients (17%) succumbed to HLH (P  .1563).
Among patients with HLH, HLH-associated lethality was signifi-
cantly higher in SAP-deficient patients (11 of 18, 61%) than in
XIAP-deficient patients (5 of 22, 23%) (*P  .0230). HLH
Table 1. Characteristics of patients with mutations in SH2D1A/SAP (XLP-1)
Patient
ID*
SH2D1A/SAP
mutation
SAP
protein
HLH (age in
years at
diagnosis)
EBV at
first HLH
HLH
relapses
(age in
years at
relapse)
SM (age in
years at
diagnosis)
Hypo- (age in
years at
diagnosis)
Lymphoma
(age in
years at
diagnosis)
Other
manifestations
(age in years at
diagnosis) Outcome (age in years)
S1.1 E67G  NA   13  Alive, well (19)
S1.2 E67G  3   (25)   (26) 34  Alive, under lymphoma
treatment (34)
S1.3 E67G 15 ?    7, 30  Alive, under lymphoma
treatment (30)
S1.4 E67G  NA   (4)†   Alive, well, IVIG (10)
S2.1 I96X  4 ?  ? ?   Died (4, HLH)
S3.1 del. of exons 1-4  NA  †  Chronic gastritis, Alive, well, IVIG (20)
S3.2 del. of exons 1-4  NA  †  IM (2), chronic
gastritis
Alive, well, IVIG (20)
S4.1 R55X  NA   40  Alive, well (42)
S4.2 ND 6       Died (6, HLH)
S5.1 del. of exon 2 3.7   ? ?   Died (3.7, HLH)
S5.2 ND  NA  ? 5  Died (5, lymphoma)
S6.1 del. of exon 1 2.2    ?   Died (2.2, HLH)
S7.1 R55X  2.5    ?  Recurrent
infections
HSCT (2.7), alive (11)
S8.1 X129RfsX141  2.4   (9)   (3)†   First HSCT (9); second HSCT
(10); died (10.2)
S8.2 ND 2    ?   Died (2, HLH)
S9.1 C42Y /  NA   2  Alive (18)
S9.2 C42Y  NA   (1)†   Alive, well, IVIG (16)
S10.1 R55Q 14 ?  ? ?   Died (14, HLH)
S11.1 X129R fsX141   NA     Alive, well, NT, IVIG (22)
S11.2 X129R fsX141  NA ? ?  Recurrent
pneumonia
Alive, well (66)
S11.3 X129R fsX141  NA     Alive, well, IVIG (15)
S11.4 X129R fsX141  NA   (9) 7  Alive, well, IVIG (19)
S12.1 del. of exon 3  19     (10)† 11 T (22) Alive, T, IVIG (23)
S12.2 del. of exon 3 19 ?    (19)† 20  Died (21, lymphoma)
S13.1 N82FfsX103 ND 10§   (12, EBV)  (9)‡ ?   Died (12, HLH)
S14.1 del. of exons 1-4 3.5      HUS (3.5) Died (3.6, HLH)
S15.1 A22P   NA   (13)†   Alive, well, IVIG (25)
S15.2 ND 3.6 ?   ?   Died (3.6, HLH)
S15.3 ND  NA  (45)‡ ?   Died (69, myelodysplasia)
S16.1 del. of exons 2-4  3.1    ?   Died (3.1, HLH)
S17.1 M1T   NA    (4)†  IM (2.4) Alive, NT, IVIG (20)
S18.1 No mutation  16§ ?    (15)† 9  Died (17, HLH)
S19.1 del. of exons 1-4  3.3     Hypopigmented
hair
HSCT (3.7), died (3.8)
SM indicates recurrent splenomegaly or hepatosplenomegaly; Hypo-, hypogammaglobulinemia; NA, not applicable; del., deletion; ?, unknown; IM, infectious
mononucleosis; ND, not done; HSCT, hematopoietic stem cell transplantation; N, neutropenia; T, thrombocytopenia; and HUS, hemolytic uremic syndrome.
*Patient identification: S indicates SAP-deficiency, the first number corresponds to the family and the second to the individual patient.
†With recurrent respiratory infections; indicates yes or positive;, no or negative.
‡Recurrent splenomegaly or hepatosplenomegaly associated with intermittent fever, anemia, and cytopenia.
§Diagnosed as incomplete HLH.
1524 PACHLOPNIK SCHMID et al BLOOD, 3 FEBRUARY 2011  VOLUME 117, NUMBER 5
 For personal use only. at UNIVERSITAETSSPITAL on May 30, 2011. bloodjournal.hematologylibrary.orgFrom 
relapsed in 2 of 7 SAP-deficient HLH-survivors (29%), whereas
11 of 14 XIAP-deficient HLH-survivors (79%, 3 unknown) had
 1 relapse of HLH (P  .055).
Six of the 18 SAP-deficient patients with HLH (33%) had
proven neurologic involvement with mostly (5 of 6, 83%) lethal
outcome, whereas 2 of 22 of XIAP-deficient patients with HLH
(9%) had neurologic involvement with less mortality (1 of 2, 50%).
EBV infection was the most-frequent identified trigger of the
first HLH episode in the SAP-deficient (11 of 12, 92%, 6 unknown)
and XIAP-deficient (15 of 18, 83%, 4 unknown) patients (P  .63)
(Table 3). Only PS13.1, PX1.6, PX10.1, and PX11.1 had a first
HLH episode in the absence of a proven EBV-infection, whereas
the EBV status of 6 SAP-deficient patients and 4 XIAP-deficient
patients is not known. PX1.6 and PX4.2 subsequently experienced
an HLH-relapse with positive EBV polymerase chain reaction. In
2 patients, herpes simplex virus type 1 (HSV-1) and human
herpesvirus type 6 (HHV-6) were detected in the blood by
polymerase chain reaction in the course of their first HLH episode.
Of note, in several XIAP-deficient patients, other viruses than EBV
were tested, including cytomegalovirus, parvovirus B19, HSV,
HHV-6, HHV-8, HIV, human T-cell leukemia virus, adenovirus,
and varicella-zoster virus. All were negative.
Splenomegaly and incomplete forms of HLH
Recurrent splenomegaly occurring in the absence of systemic HLH
and often associated with fever and cytopenia (consisting of
pancytopenia, bicytopenia, thrombocytopenia, and anemia) was
frequently observed in XIAP-deficient patients (20 of 23, 87%,
7 unknown), whereas it was only found in 2 of 29 SAP-deficient
patients (7%, 4 unknown; ***P  .0001; Table 3). In 8 XIAP-
deficient patients, episodes of splenomegaly occurred before they
developed HLH and were the first clinical sign of the disease.
Overall, although 3 patients with splenomegaly up to now did not
Table 2. Characteristics of patients with mutations in XIAP (XLP-2)
Patient
ID*
XIAP
mutation
XIAP
protein
HLH (age
in
years at
diagnosis)
EBV at first
HLH
HLH relapses
(age in years
at relapse)
SM (age in
years at
diagnosis)
Hypo-
(age in
years at
diagnosis)
Chronic
colitis
(age in
years at
diagnosis)
Other
manifestations
(age in years at
diagnosis)
Outcome (age in
years)
X1.1 E99KfsX129 5  ? ?   ? Alive, well (8)
X1.2 E99KfsX129  5.3  ?  (5)   ? Alive, well (11)
X1.3 E99KfsX129 2.5  ?  (2.5)   ? Alive, well, IVIG (14)
X1.4 E99KfsX129  7.8    (6)   (4) Cholangitis (23) Alive, ileitis (23)
X1.5 E99KfsX129 3    (3)    Alive, well (30)
X1.6 E99KfsX129  0.8  (HHV-6/)  (EBV)  (1)‡ (10)   HSCT (11), died (11)
X1.7 ND 1.5† ?   (1.5)‡ (42)  (41) Cholangitis (41) Died (42, colitis)
X2.1 I397FfsX414  1.2    (1)‡    HSCT (1.6), died
(d13, HLH)
X3.1 E118X  23    (22) (22)   Alive, well, IVIG (39)
X3.2 ND 0.5 ?  ? ?  Died (0.5, HLH)
X3.3 ND 20   ? ?  Died (20, HLH)
X3.4 E118X   NA   (7)    Alive, well, SM (10)
X4.1 del. of exon 2  20   (21,EBV)  (1)‡    Alive, well (28)
X4.2 del. of exon 2  10 ?  (11, EBV)  (6)‡    Alive, well (15)
X5.1 D130GfsX140  2.5   (3.4-3.6)  (1)    HSCT (3.6), died (4)
X5.2 ND 0.1 ?  ? ?   Died (0.1, HLH)
X5.3 ND 3.5   ? ?   Died (3.5, HLH)
X6.1 R238X  1.7   ‡    Alive, recurrent HLH (3)
X7.1 I397NfsX405  2.7   (3.2-3.5,
EBV)
 (2.7)    Alive, recurrent HLH
(3.5)
X8.1 E434AfsX457 / 15.5       Alive, well (16)
X9.1 G466X / 8†    (8)‡  (8)§   Alive, well, SM (27)
X9.2 G466X /  NA   (21)  (21)§   Alive, well, SM (30)
X9.3 G466X /  NA   (4)‡   (12) Recurrent
infections
Alive, colitis (14)
X9.4 G466X /  NA   (22)‡  (10)§  Chronic liver
failure (22)
Died (29, liver failure),
IVIG,
X9.5 G466X /  NA      Alive, well (39)
X9.6 ND  NA  ? ?  ? Died (27, colitis)
X9.7 ND  NA  ‡ ?  Recurrent
infections
Died (52, pneumonia)
X10.1 T470S  8†  (HSV-1)    (4)§  Cryptococcosis
(4)
Alive, well, IVIG (8)
X11.1 R381X  0.9†  NA  (0.6)‡    HSCT (1.2), died (1.4)
X11.2 ND ? ? ? ? ? (4) ? Died (4, colitis)
SM indicates recurrent splenomegaly or hepatosplenomegaly; Hypo-, hypogammaglobulinemia; ?, unknown; HSCT, hematopoietic stem cell transplantation; ND, not
done; NA, not applicable; and del., deletion.
*Patient identification: X indicates XIAP deficiency, the first number corresponds to the family and the second to the individual patient; indicates yes or positive;, no or
negative; and/, weakly positive.
†Diagnosed as incomplete HLH.
‡Recurrent splenomegaly or hepatosplenomegaly associated with intermittent fever, anemia, and cytopenia.
§With recurrent respiratory infections.
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develop HLH, the others subsequently developed HLH within a
period of time, varying from a few months to 19 years. In
2 XIAP-deficient patients, transient pancytopenia with spleno-
megaly was noticed after vaccinations against measles, mumps, and
rubella or measles and rubella. Importantly, none of the XIAP-
deficient patients developed B-cell lymphoproliferative disease.
PX4.1 underwent splenectomy at the age of 21 years, and
histopathologic examination of the spleen showed reduced white
pulp areas, and red pulp was extended with a mild fibrosis
(supplemental Figure 2 top left). In the white pulp, most of the
lymphocytes were CD20, whereas in the red pulp there was an
accumulation of CD3 T cells that were mostly CD8 and
cytotoxic (T-cell intracellular antigen-1; data not shown; supple-
mental Figure 2 bottom). Strikingly, features of hemophagocytosis
were observed in the red pulp (supplemental Figure 2 upper right).
Lymphocytes were negative for LMP-1 with very rare EBER
cells, suggesting that the infiltration was not related to EBV
infection (data not shown). Altogether, these observations strongly
suggest that these lymphoproliferative manifestations can be
regarded as incomplete or attenuated forms of HLH.
In addition, 3 XIAP-deficient patients had liver disease
(2 patients with cholangitis and 1 patient with chronic liver failure).
In 2 of the patients, the cholangitis was associated with colitis,
which are known to overlap.18 For patient PX1.7, histopathologic
examination of the liver showed granulomatous hepatitis in lobular
areas with foci of macrophages around necrotic hepatocytes
(supplemental Figure 3). Staining for LMP-1 was negative (data
not shown). It is unclear whether these liver diseases should also be
considered as an incomplete form of HLH.
Lymphoma
Ten of 33 SAP-deficient patients (30%) and none of the 30 XIAP-
deficient patients developed lymphoma (Tables 1-3; supplemental
Figure 1B; ***P .001). Mean age at diagnosis of lymphoma was
15 years (range, 2-40 years). Diagnoses were non-Hodgkin lymphoma
(n 9), including EBV-positive Burkitt lymphoma (n 6) and EBV-
negative (n 3). Lymphomas were localized in the ileocecal (n 5),
cerebral19 (n 1), cervical (n 2), and spinal (n 2) regions, and for
one the origin was not known. One patient (PS1.3) had a second
lymphoma at the age of 30 years, 23 years after the first one, and one
patient (PS15.3) had myelodysplasia.
Dysgammaglobulinemia
Hypogammaglobulinemia was documented in 14 SAP-deficient
patients (14 of 21, 67%) and in 8 XIAP-deficient patients (8 of 24,
33%) (*P  .0377) (Tables 1-3). Thirty percent (10 of 33) of
SAP-deficient patients and 13% (4 of 30) of XIAP-deficient
patients received intravenous immunoglobulin (IVIG) substitution
(P  .1357) (supplemental Figure 1C). Interestingly, hypogamma-
globulinemia was transient in 2 of the 8 XIAP-deficient patients.
PX3.1 was substituted with IVIG between the age of 23 and
35 years, currently, 4 years after stopping IVIG, immunoglobulin
levels remain within the normal range, and the patient does not
experience recurrent respiratory infections. Two XIAP-deficient
patients developed hypergammaglobulinemia, with higher than
normal IgA and IgM levels in PX9.3 and elevated IgG and IgM
levels in PX11.1, respectively.
Severe infections were noted in several SAP- and XIAP-
deficient patients with hypogammaglobulinemia before initiation
of the IVIG substitution when treated. Ten of the 14 SAP-deficient
and 4 of the 8 XIAP-deficient patients had recurrent respiratory tract
infections. Rare severe infections caused by Haemophilus influenzae,
Mycoplasma pneumoniae, Streptococcus pneumoniae, Staphylococcus
aureus, and Cryptococcus neoformans were also observed in SAP- and
XIAP-deficient patients (supplemental Table 1).
Colitis
Chronic colitis with hemorrhagic diarrheas or rectal bleeding or
both evoking inflammatory bowel disease was observed in 5 of
30 XIAP-patients (17%) but in none of 33 SAP-deficient patients
(*P  .0203; Tables 1-3). In PX1.4, colitis initially responded to
immunosuppressive treatment with corticosteroids and cyclospor-
ine A. However, corticosteroids could not be withdrawn, and the
Figure 1. Comparison of HLH phenotypes and survival curves of SAP-deficient (XLP-1) and XIAP-deficient (XLP-2) patients. Kaplan-Meier survival curves were
constructed on the basis of data presented in Table 1 and Table 2. Statistical analyses with log-rank tests. (A) Percentage of XLP-1/SAP and XLP-2/XIAP patients without HLH
phenotype (P  .099). (B) Overall survival curves for XLP-1/SAP and XLP-2/XIAP patients (P  .948).
Table 3. Comparison of XLP-1 and XLP-2 phenotypes
SAP-/Y, n (%) XIAP-/Y, n (%) P*
HLH 18 of 33 (55) 22 of 29 (76) NS
HLH relapses (/HLH-survivors) 2 of 7 (29) 11 of 14 (79) NS
EBV at first HLH 11 of 12 (92) 15 of 18 (83) NS
Fatal HLH 11 of 33 (33) 5 of 30 (17) NS
Fatal HLH (/HLH patients) 11 of 18 (61) 5 of 22 (23) .0230
Hypogammaglobulinemia 14 of 21 (67) 8 of 24 (33) .0377
Lymphoma 10 of 33 (30) 0 of 30 (0) .0010
Cytopenias (in the absence of
full-blown HLH)
4 of 33 (12) 11 of 21 (52) .0020
Splenomegaly (in the absence
of full-blown HLH)
2 of 29 (7) 20 of 23 (87) .0001
Hemorrhagic colitis 0 of 33 (0) 5 of 30 (17) .0203
*Calculated with Fisher exact tests.
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addition of azathioprine could not prevent the recurrence of
symptoms. Anti–tumor necrosis factor-	 mAb treatment (inflix-
imab) provided partial improvement. Recently, a colectomy was
performed, but the patient now has terminal ileitis. In PX1.7, severe
hemorrhagic colitis was associated with portal hypertension and
massive gastroduodenal bleeding that lead to death of this patient.
Patients PX9.6 and PX11.2 also suffered from chronic colitis and
most probably died of intestinal hemorrhage.
Histopathologic examination of intestinal mucosa biopsy speci-
mens was performed in 3 patients, PX1.4, PX1.7, and PX9.3.
Representative images are shown in Figure 2. Hemorrhagic
ulcerations of the colon associated with mononuclear infiltration
consisting of lymphoid cells and plasma cells in the lamina propria
were observed (Figure 2 left top). Crypt architecture was mostly
preserved, except for rare crypt abscesses (Figure 2, left bottom),
but frequent apoptotic crypt cells were seen (supplemental Figure
4). The lymphoid cells were mostly CD3 and CD8 with some
lymphocytes expressing CD25 with numerous eosinophils (in
PX1.4) (Figure 2; supplemental Figure 4). CD20 cells were rare,
EBER staining was negative (not shown), and there was no granuloma
formation. Microbiologic cultures were negative in all 3 cases.
Rare clinical manifestations
Rare clinical features (supplemental Table 1), each observed in
1 SAP-deficient patient, were hemolytic uremic syndrome associ-
ated with HLH, vasculitis, and arthritis. Clinical features, each
observed in 1 XIAP-deficient patient, were Kawasaki syndrome
and psoriasis. Additional infections in patients without hypogamma-
globulinemia were caused by Pseudomonas aeruginosa (1 SAP-
deficient patient), recurrent measles (1 XIAP-deficient patient), and
HSV-(1 XIAP-deficient patient). Of note, 2 SAP-deficient patients
(PS3.1 and PS3.2) had chronic gastritis.20
Survival and outcome
Sixteen of 33 SAP-deficient patients and 12 of 30 XIAP-deficient
patients died at a mean age of 11 years (range, 2-69 years) and
16 years (range, 0.1-52 years), respectively. Survival rates did not
differ between both patient groups (P  .93; Figure 1B), and the
proportions of whom reached adulthood (age 16 years) were
similar in both groups (17 of 33 SAP-deficient patients [52%] and
Figure 2. Histology of the large bowel of PX1.7 with XIAP deficiency. (Top left) On hematoxylin and eosin at low magnification (100), a large ulceration is seen, indicated by an
arrow. (Bottom left) Higher magnification (200) shows a massive polymorphic inflammatory infiltrate associated with a crypt abscess (indicated by the arrow). (Central right)
Immunostaining with anti-CD3 shows frequent lymphoid T cells (on the right,200), some of them express the activation marker CD25 (400, inset).
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13 of 30 XIAP-deficient patients [43%]). Mortality was related to
HLH (11 SAP- and 5 XIAP-deficient patients), lymphoma (2 SAP-
deficient patients), myelodysplasia (1 SAP-deficient patient), coli-
tis (3 XIAP-deficient patients), hepatitis (1 XIAP-deficient patient),
complications of hematopoietic stem cell transplantation (2 SAP-
and 4 XIAP-deficient patients), and pneumonia (1 XIAP-deficient
patient). Mean age at last follow-up was 24.9 years (range,
10-66 years) for SAP-deficient patients and 17.5 years (range,
0.7- 39 years) for XIAP-deficient patients. Among the surviving
17 SAP-deficient patients, 4 are well without any treatment,
10 receive IVIG substitution, 2 are currently treated for a lym-
phoma, and 1 had successful hematopoietic stem cell transplantation.
Among the surviving 17 XIAP-deficient patients, 10 are well
without any treatment (among them 3 with splenomegaly), 2
received recently anti-CD20 antibody treatment because of EBV-
related HLH, 2 are under IVIG substitution, 1 has terminal ileitis
after colectomy, 1 has colitis treated with mesalazine and azathio-
prine, and 1 has recurrent HLH treated with cyclosporine A and
dexamethasone. One XIAP-deficient and 2 SAP-deficient patients
have never developed clinical signs and are considered to be
asymptomatic.
Discussion
We report the first comparison of the clinical phenotypes of SAP-
and XIAP-deficient patients. The present study was based on a
retrospective analysis with data from medical records on 33 SAP-
and 30 XIAP-deficient patients. The relatively small size of both
cohorts obviously implies that data should be interpreted with
caution.
The overall clinical phenotypes of the affected persons matched
with the phenotypes previously reported.2,7,9,21 In accordance to
previous studies, we did not observe any genotype-phenotype
correlation in the SAP-deficient patients. However, in our cohort of
XIAP-deficient patients, we noticed that XIAP-deficient patients
carrying non-null mutations had a tendency to be less prone to
develop HLH by contrast to patients with null mutations. However,
other genetic or environmental factors may contribute to the variety
of phenotypes observed in XLP-1 and XLP-2.
HLH occurred both in SAP- and in XIAP-deficient patients but
with more frequent neurologic involvement and fatal outcome in
SAP-deficient patients than in XIAP-deficient patients. Spleno-
megaly often associated with cytopenia and fever was more
frequent in XIAP-deficient patients than in SAP-deficient patients.
Histologic analysis of one spleen showed accumulation of acti-
vated CD8 T cells and hemophagocytosis without EBV cells.
These symptoms probably represent incomplete forms of HLH. In
addition, HLH relapses seemed to be more common in XIAP- than
in SAP-deficient patients who survived HLH. Together, these
findings suggest that HLH has a less severe disease course in
XIAP- deficient patients than in SAP-deficient patients.
In most of the patients from both groups, the trigger of HLH
was an EBV infection (
 80%); EBV may favor HLH by eliciting
a potent CD8 T-cell response. It is also postulated that SAP and
possibly XIAP are associated with activation pathways that are
more important in triggering selective cytotoxicity toward B cells.22-
27 HLH in most hereditary conditions such as FHL, Griscelli
syndrome type II, and Chediak-Higashi syndrome shares common
pathophysiologic mechanisms, that is, global impaired cytotoxicity
responses that lead to the inability of effector lymphocytes to kill
infected cells and antigen-presenting cells.28 In mice and humans,
SAP-deficient CD8 T and NK cells exhibit defective cytotoxicity
responses caused by abnormal functions of SLAM receptors.29
This could explain the occurrence of HLH in SAP-deficient
patients.22-27 In contrast, NK-cell and T-cell cytotoxic responses
appear to be preserved in XIAP-deficient patients7,9 (C. Synaeve
and S.L., unpublished data, 2009 and 2010). This might account for
the lower severity of the HLH in the XIAP deficiency. Hence, the
precise immune defects responsible for HLH in XIAP deficiency
remain to be elucidated.
Only XIAP-deficient patients were at risk for chronic colitis
with often a lethal outcome. This phenotype seems that is may be
even worse than HLH, because the mortality in the group of
patients with colitis (3 of 5) has a tendency to be higher than in the
group with HLH (5 of 22). Histopathologic analysis of intestinal
mucosal biopsy specimens showed an inflammatory process with
an accumulation of activated T cells (and eosinophils in one
patient) that could evoke inflammatory bowel disease. Interest-
ingly, a recent report indicates that XIAP is involved in nucleotide-
binding oligomerization domain containing 2 (NOD2) activation
which is an intracellular pattern recognition receptor of the
NOD-like receptor family.30 Importantly, NOD2 is a key suscep-
tibility gene for Crohn disease.31 Thus, defects in XIAP might
lead to defective NOD2 responses as an additive risk factor for
colitis in some of these patients. Of note, however, NOD2 was
sequenced in 2 XIAP-deficient patients with colitis, and none
had the genotype shown to be a risk factor for Crohn disease
(J.P. Hugot and S.L., unpublished data, June 2006).
One striking difference between XLP-1 and XLP-2 was that
only SAP-deficient patients developed lymphoma, although it
could not be formally excluded that XIAP-patients might
develop lymphomas in the future. In SAP-deficiency, the
occurrence of lymphomas may be explained by defective
immunosurveillance of hematopoietic cells, resulting from
alterations in SLAM receptor-mediated NK- and T-cell cytotox-
icity responses,22-24,26 but also by the proapoptotic functions that
have been assigned to SAP.32,33
Another common finding shared by XLP-1 and XLP-2 is the
hypogammaglobulinemia. Interestingly, 2 XLP-2 patients recov-
ered from hypogammaglobulinemia, which so far seems not to be
the case for XLP-1 patients. Numerous studies in mice and humans
have documented that impaired antibody production found in
XLP-1 resulted from a block in germinal center formation, leading
to defects in the differentiation of Ig-isotype–switched memory
B cells.34-36 In most of the XIAP-deficient patients, Ig-isotype–
switched memory B cells are not found to be decreased7 (S. Siberil
and S.L., unpublished data, 2008 and 2009). In XIAP deficiency,
hypogammaglobunemia could be the consequence of increased
activation-induced cell death of B cells, a hypothesis that needs to
be tested.
In conclusion, the present comparison of the clinical features of
SAP- and XIAP-deficient patients shows that SAP deficiency and
XIAP deficiency share a main phenotype, that is, EBV-induced
HLH. This similarity raises the possibility of a functional/
molecular link between SAP and XIAP proteins. Alternatively,
impairment of 2 independent pathways, both important in EBV
immunity, could lead to a shared phenotype. Nevertheless, we also
demonstrate that XLP-1 and XLP-2 can be distinguished on several
clinical aspects, which could be helpful for diagnosis and therapeu-
tic decisions.
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